Kenvue Inc. maker of healthcare products such as Tylenol®, Neutrogena®, and Listerine®, today announced a five-year partnership with Microsoft to build a solid foundation for digital transformation through advanced AI technologies. These technologies include machine-assisted collaboration, predictive analytics, intelligent agents, digital twins, and generative AI. By advancing predictive and AI-powered capabilities, Kenvue aims to set new standards for innovation in commerce, operations, and technology, delivering enhanced customer experiences, increased productivity, and sustainable growth.

Over the next five years, Kenvue will scale its use of Microsoft Azure to leverage its broad range of services, including data analytics and AI. Integrating Azure services will enhance predictive capabilities and human-machine collaboration. Kenvue will also drive innovation, perfect go-to-market strategies, enhance the customer experience, and streamline business operations to bring the power of everyday care into the hands of consumers worldwide.

The real-time algorithms and solutions based on traditional and generative AI available through the move to Azure provide Kenvue with the following advantages:

• Accelerate product development, improve formulations and optimize clinical research data to provide consumers with access to cutting-edge healthcare solutions;
• Further developing data-driven go-to-market strategies, personalizing the customer experience, adapting product recommendations, and improving omnichannel interactions;
• Deepen customer collaboration and increase retail excellence and visibility through algorithmic distribution, supported by advanced forecasting and intelligent automation to improve inventory management and reduce losses;
• Optimizing business processes and increasing efficiencies to unlock new growth opportunities and leveraging emerging platforms.

"This promising collaboration will support Kenvue on its journey to becoming the undisputed leader in consumer health," explains Bernardo Tavares, Chief Technology and Data Officer at Kenvue. "By harnessing the full potential of data and AI, our teams can accelerate product development, optimize decisions, and create seamless, personalized customer experiences, while keeping data protection and consumer trust at the forefront at all times. By transforming our digital operations, we aim to develop predictive business solutions and win new customers every day."

Shelley Bransten, Corporate Vice President, Global Industry Solutions at Microsoft, added: "This collaboration demonstrates the transformative potential of AI. Together, we strive for a future where predictive capabilities and human-machine coordination serve as powerful, trusted tools to improve consumer health and unlock groundbreaking innovations."

Kenvue is already testing systems and tools that integrate Microsoft Azure AI, Microsoft 365 Copilot, and Copilot Studio in supply chain management and operations, content creation, and various productivity use cases. By advancing predictive and AI-powered capabilities, Kenvue is working with the Kenvue ecosystem of digital partners to set new standards for consumer health innovation.

About Kenvue

Kenvue Inc. is the world's largest pure-play healthcare company by revenue. Our iconic brands, Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, are built on more than a century of heritage. They are backed by science and recommended by healthcare professionals around the globe. At Kenvue, we recognize the outstanding power of everyday care. Every day, our teams work to put that power in the hands of consumers and earn a place in their hearts and homes. More information is available at www.kenvue.com .

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding a five-year collaboration with Microsoft to transform Kenvue's digital operations. Forward-looking statements can be identified by terminology such as "plans," "expects," "will," "anticipates," "estimates," and similar expressions. Undue reliance should not be placed on forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results may differ materially from the expectations and projections of Kenvue and its affiliates.

A list and discussion of risks, uncertainties, and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024, and subsequent Quarterly Reports on Form 10-Q and other filings, which are available at www.kenvue.com or upon request from Kenvue. Kenvue and its subsidiaries assume no obligation to update any forward-looking statements, whether as a result of new information, future events or developments, or otherwise.

The original language in which the text is published is the official and authorized version. Translations are provided for clarity. Only the language version originally published is legally binding. Therefore, please compare translations with the original language version of the publication.

Contact:

Melissa Witt,
media@kenvue.com

 

Source: businesswire.com/

Report Abuse